[1] Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019; 70, 531−44. doi:  10.1016/j.jhep.2018.10.033
[2] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med, 2018; 18, 245−50.
[3] George J, Anstee Q, Ratziu V, et al. NAFLD: The evolving landscape. J Hepatol, 2018; 68, 227−9. doi:  10.1016/j.jhep.2017.11.016
[4] Li J, Zou BY, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019; 4, 389−98. doi:  10.1016/S2468-1253(19)30039-1
[5] Khan RS, Bril F, Cusi K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology, 2019; 70, 711−24.
[6] Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int, 2016; 36, 275−83. doi:  10.1111/liv.12912
[7] Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol, 2021; 110, 921−37. doi:  10.1007/s00392-020-01709-7
[8] Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci, 2016; 17, 562. doi:  10.3390/ijms17040562
[9] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab, 2020; 42, 101092. doi:  10.1016/j.molmet.2020.101092
[10] Ren XX, Chen ZA, Zheng S, et al. Association between triglyceride to HDL-C Ratio (TG/HDL-C) and insulin resistance in Chinese patients with newly diagnosed type 2 diabetes mellitus. PLoS One, 2016; 11, e0154345. doi:  10.1371/journal.pone.0154345
[11] Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev, 2019; 40, 1367−93. doi:  10.1210/er.2019-00034
[12] Nemes K, Åberg F. Interpreting lipoproteins in nonalcoholic fatty liver disease. Curr Opin Lipidol, 2017; 28, 355−60. doi:  10.1097/MOL.0000000000000427
[13] Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol, 2016; 10, 420−5.e1. doi:  10.1016/j.jacl.2015.12.026
[14] DeFilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013; 227, 429−36. doi:  10.1016/j.atherosclerosis.2013.01.022
[15] Ma ZM, Xu CN, Kang XP, et al. Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Transl Med, 2020; 18, 133. doi:  10.1186/s12967-020-02296-x
[16] Jaruvongvanich V, Ahuja W, Wirunsawanya K, et al. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2017; 29, 1031−5. doi:  10.1097/MEG.0000000000000931
[17] Wei FJ, Li JX, Chen C, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: A 4-year prospective cohort study. Front Endocrinol, 2020; 11, 179. doi:  10.3389/fendo.2020.00179
[18] Zheng XY, Gong LL, Luo R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis, 2017; 16, 202. doi:  10.1186/s12944-017-0531-5
[19] Liu CQ, He CM, Chen N, et al. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. Sci Rep, 2016; 6, 38605. doi:  10.1038/srep38605
[20] Kocak MZ, Aktas G, Erkus E, et al. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras (1992), 2019; 65, 9−15. doi:  10.1590/1806-9282.65.1.9
[21] Aktas G, Kocak MZ, Bilgin S, et al. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male, 2020; 23, 1098−102. doi:  10.1080/13685538.2019.1678126
[22] Kurtkulagi O, Tel BMA, Kahveci G, et al. Hashimoto's thyroiditis is associated with elevated serum uric acid to high density lipoprotein-cholesterol ratio. Rom J Intern Med, 2021; 59, 403−8.
[23] Aktas G, Khalid A, Kurtkulagi O, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med, 2022; 134, 297−302. doi:  10.1080/00325481.2022.2039007
[24] Zhang YN, Wang QQ, Chen YS, et al. Association between serum uric acid to HDL-cholesterol ratio and nonalcoholic fatty liver disease in lean Chinese adults. Int J Endocrinol, 2020; 2020, 5953461.
[25] Gao X, Fan JG, Study Group of Liver and Metabolism, et al. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes, 2013; 5, 406−15. doi:  10.1111/1753-0407.12056
[26] Petersmann A, Nauck M, Müller-Wieland D, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes, 2018; 126, 406−10. doi:  10.1055/a-0584-6223
[27] Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol, 2019; 16, 182−241.
[28] Xu CF. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. Hepatol Int, 2016; 10, 286−93. doi:  10.1007/s12072-015-9682-5
[29] Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A meta-analysis. Acta Med Indones, 2017; 49, 136−47.
[30] Liu ZT, Que SP, Zhou L, et al. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: A meta-analysis of prospective studies. Sci Rep, 2015; 5, 14325. doi:  10.1038/srep14325
[31] Zhou YJ, Wei FF, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem, 2016; 49, 636−42. doi:  10.1016/j.clinbiochem.2015.12.010
[32] Maylor BD, Zakrzewski-Fruer JK, Orton CJ, et al. Beneficial postprandial lipaemic effects of interrupting sedentary time with high-intensity physical activity versus a continuous moderate-intensity physical activity bout: A randomised crossover trial. J Sci Med Sport, 2018; 21, 1250−5. doi:  10.1016/j.jsams.2018.05.022
[33] Chen HY, Li SC, Chen LF, et al. The effects of cigarette smoking and smoking cessation on high-density lipoprotein functions: implications for coronary artery disease. Ann Clin Biochem, 2019; 56, 100−11. doi:  10.1177/0004563218788386
[34] Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function. Int J Mol Sci, 2020; 21, 8985. doi:  10.3390/ijms21238985
[35] Waldman B, Jenkins AJ, Davis TME, et al. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care, 2014; 37, 2351−8. doi:  10.2337/dc13-2738
[36] Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol, 2015; 3, 78−84. doi:  10.14218/JCTH.2014.00037
[37] Du TT, Sun XX, Yuan G, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism, 2016; 65, 1391−8. doi:  10.1016/j.metabol.2016.06.006
[38] Kosekli MA, Kurtkulagii O, Kahveci G, et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev Assoc Med Bras (1992), 2021; 67, 549−54. doi:  10.1590/1806-9282.20201005
[39] Sun DQ, Wu SJ, Liu WY, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets, 2016; 20, 375−87. doi:  10.1517/14728222.2016.1096930
[40] Arrese M, Cabrera D, Kalergis AM, et al. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci, 2016; 61, 1294−303. doi:  10.1007/s10620-016-4049-x